James M. Inhofe sold MSACX (MSACX)
James M. Inhofe (R-OK), a U.S. Senator, has disclosed 1 trade in MSACX (MSACX) since 2015, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: James M. Inhofe sold $15,001 - $50,000 of MSACX (MSACX) on July 9, 2015. Since that trade, MSACX is up +13.09% against the S&P 500 up +333.06%, an outperformance of -319.97%.
Data updated
James M. Inhofe's MSACX trades vs the price
MSACX is up +13.09% since James M. Inhofe sold on July 9, 2015, versus +333.06% for the S&P 500.
Performance since this trade
All James M. Inhofe MSACX trades
James M. Inhofe & MSACX trading FAQ
Is it legal for James M. Inhofe to trade MSACX (MSACX) stock?
Yes. Members of Congress are allowed to trade individual stocks, including MSACX (MSACX), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did James M. Inhofe sell MSACX?
James M. Inhofe disclosed a sale of $15,001 - $50,000 of MSACX (MSACX) on July 9, 2015, according to public STOCK Act filings.
How has MSACX performed since James M. Inhofe's trade?
Since James M. Inhofe sold MSACX on July 9, 2015, the stock is up +13.09%, versus +333.06% for the S&P 500 over the same period, an outperformance of -319.97%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional MSACX trades?
Quantellect tracks every disclosed congressional trade in MSACX (MSACX) on the MSACX congressional trading page, which aggregates filings across all members of Congress.
James M. Inhofe's MSACX tradesAll congressional filings for MSACXJames M. Inhofe's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.